Ku80 gene knockdown by the CRISPR/Cas9 technique affects the biological functions of human thyroid carcinoma cells

Yali Fan1, Jianying Li1, Wei Wei2

  • 1Department of Respiratory Medicine, Xi'an Central Hospital, The Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710003, P.R. China.

Oncology Reports
|October 4, 2019
PubMed

Insights

Ku80 protein is elevated in thyroid carcinoma (TC) and drives cancer progression. Silencing Ku80 in TC cells reduced proliferation and invasion, suggesting Ku80 as a potential therapeutic target for thyroid cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Thyroid carcinoma (TC) is a significant health concern.
  • The role of Ku80 in the development and progression of TC requires further elucidation.

Purpose of the Study:

  • To investigate the role of Ku80 in thyroid carcinoma.
  • To assess the correlation between Ku80 expression and key cancer markers.

Main Methods:

  • Immunohistochemistry on 86 thyroid tissue samples.
  • Reverse transcription-quantitative PCR and CRISPR/Cas9 gene silencing in TC cells.
  • Antibody array analysis to identify related genes.

Main Results:

  • Ku80 protein levels were significantly higher in TC tissues compared to adjacent non-neoplastic tissues.
  • Ku80 expression correlated with nuclear factor-κB (NF-κB) activation and RET/TC expression.
  • Ku80 knockdown in papillary TC cells reduced proliferation, invasion, and colony formation, while increasing apoptosis.

Conclusions:

  • Ku80 plays a crucial role in promoting thyroid carcinoma malignancy.
  • Ku80 is associated with NF-κB activation and RET/TC expression in TC.
  • Targeting Ku80 may offer a novel therapeutic strategy for thyroid cancer.